Terminated NA INTERVENTIONAL 2-arm NCT01615146

Outpatient Platelet Transfusions in Myelodysplastic Syndromes and Leukemia: The OPTIMAL Pilot (OPTIMAL)

Sponsor: Canadian Blood Services

Conditions Leukemia Myelodysplastic Syndrome

Updated 5 times since 2017 Last updated: Sep 1, 2015 Started: Jun 30, 2012 Primary completion: Jun 30, 2015 Completion: Jun 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Poor recruitment

Other terminated trials from Canadian Blood Services

COVID-19 · Phase PHASE3 · Jun 2021

See all terminations from Canadian Blood Services

Other Leukemia trials with similar outcome

Browse all Leukemia trials

This NA trial investigates Leukemia and Myelodysplastic Syndrome and is currently terminated or withdrawn. Canadian Blood Services leads this study, which shows 5 recorded versions since 2012 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated NA
Jul 2024 — Sep 2024 [monthly]

Terminated NA
Jan 2021 — Jul 2024 [monthly]

Terminated NA
Jun 2018 — Jan 2021 [monthly]

Terminated NA
Jan 2017 — Jun 2018 [monthly]

Terminated NA

First recorded

Jun 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Canadian Blood Services
Canadian Institutes of Health Research (CIHR)
Ottawa Hospital Research Institute

Data source: Ottawa Hospital Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ottawa, Canada